For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Medarex Inc.

USPTO Granted Patents = 152

CIPO Patents = 13

EPO Patents = 30

Forward Citations = 6,301

Loading Chart...

Loading Chart...

199 inventors (with patents filed for the assignee):

Sanjeev Gangwar (26 out of 73 patents)

Haichun Huang (23 out of 80 patents)

Josephine M Cardarelli (21 out of 43 patents)

4. Alan J Korman (20 out of 87 patents)

5. David J King (16 out of 53 patents)

6. Robert F Graziano (16 out of 23 patents)

7. David B Passmore (15 out of 25 patents)

8. Tibor P Keler (15 out of 40 patents)

9. Nils Lonberg (14 out of 66 patents)

10. Mohan Srinivasan (14 out of 78 patents)

11. Yashwant M Deo (14 out of 21 patents)

12. Edward L Halk (13 out of 28 patents)

13. Alison Witte (13 out of 26 patents)

14. Lesley B Pickford (12 out of 12 patents)

15. Israel Lowy (11 out of 31 patents)

Core Competencies:

Neutralizing Antibodies

CTLA-4 Antibodies

Transgenic Rodents

Antiproliferative Compounds

Monoclonal Antibodies

Interferon Alpha Antibodies

Cytokine-Secreting Cells

Chemical Linkers

Protein Purification

Glypican-3 Antibodies

PD-1 Antibodies

CXCR4 Antibodies

152 patents: Sort by Forward Citations

1. 10072090 - Human anti-B7RP1 neutralizing antibodies (2018-09-11),

2. 9062111 - CTLA-4 antibody dosage escalation regimens (2015-06-23),

3. 8981071 - Human anti-B7RP1 neutralizing antibodies (2015-03-17),

4. 8945546 - IP-10 antibodies and their uses (2015-02-03),

5. 8865875 - Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions (2014-10-21),

6. 8835712 - Transgenic trasnchromosomal rodents for making human antibodies (2014-09-16),

7. 8828393 - Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist (2014-09-09),

8. 8802632 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-08-12),

9. 8784815 - Human CTLA-4 antibodies and their uses (2014-07-22),

10. 8779105 - Monoclonal antibodies to programmed death 1 (PD-1) (2014-07-15),

11. 8772543 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-07-08),

12. 8772542 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof (2014-07-08),

13. 8765415 - Methods for enhanced protein production (2014-07-01),

14. 8758757 - Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) (2014-06-24),

15. 8722870 - Nucleic acids encoding interferon alpha antibodies (2014-05-13),

Medarex Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel antibodies for the treatment of various diseases. With a focus on oncology and immunology, Medarex strives to create innovative therapies that improve patient outcomes. Through its cutting-edge research and strategic partnerships, the company aims to transform medical practices and make a positive impact in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

152 Patents

#13 in Princeton, NJ

#123 in New Jersey

#2,506 in US

#5,232 in the World

Princeton, NJ, United States of America

Medarex Inc.

Forward Citations = 6,301

199 inventors:

Sanjeev Gangwar (26 out of 73 patents)

Haichun Huang (23 out of 80 patents)

Josephine M Cardarelli (21 out of 43 patents)

4. Alan J Korman (20 out of 87 patents)

5. David J King (16 out of 53 patents)

Please report any incorrect information to support@idiyas.com

Loading…